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 Background Recent concerns about potential overdiagnosis and overtreatment of ductal carcinoma in situ of the breast (DCIS) 
render evaluation of late effects of treatment, such as cardiovascular disease (CVD), of great importance. We stud-
ied cardiovascular morbidity and mortality in a large population-based cohort of DCIS patients.
 Methods Data on all incident DCIS case patients in the Netherlands between 1989 and 2004 who were diagnosed before the 
age of 75 years were obtained (n = 10 468). CVD data was acquired through linkage with population-based regis-
tries. Standardized mortality ratios were calculated by comparing mortality in our cohort with that in the Dutch 
female population, taking into account person-years of observation. Within-cohort comparisons were based on 
multivariable competing-risk regression.
 Results Compared with the general population, 5-year survivors of DCIS had a similar risk of dying due to any cause 
(standardized mortality ratio [SMR] = 1.04; 95% confidence interval [CI] = 0.97 to 1.11) but a lower risk of dying of 
CVD (SMR = 0.77; 95% CI = 0.67 to 0.89). No difference in CVD risk was found when comparing 5-year survivors 
treated with radiotherapy with those treated with surgery only. Left-sided vs right-sided radiotherapy also did not 
increase this risk (hazard ratio [HR] = 0.94; 95% CI = 0.67 to 1.32). In a subgroup analysis of all DCIS patients diag-
nosed between 1997 and 2005, we were able to account for history of CVD and did not observe a risk difference 
between treatment groups (left-sided vs right-sided radiotherapy: HR = 0.94; 95% CI = 0.68 to 1.29).
 Conclusions After a median follow-up of 10 years, we did not find an increased risk for cardiovascular morbidity or mortality 
after radiotherapy for DCIS when comparing surgery and radiotherapy vs surgery only, nor when comparing 
radiotherapy for left-sided vs right-sided DCIS. Compared with the general population, DCIS patients have a 
decreased risk of cardiovascular death, independent of treatment.
  JNCI J Natl Cancer Inst (2014) 106(8): dju156 doi:10.1093/jnci/dju156
Since the introduction of breast cancer (BC) screening programs, 
the number of noninvasive BC diagnoses has increased substantially, 
mainly because of increased incidence of ductal carcinoma in situ 
of the breast (DCIS) (1–4). Although DCIS is generally thought to 
be a precursor of invasive BC, it remains unclear what proportion 
would progress into invasive BC if left untreated (5). Nevertheless, 
current practice is to treat all DCIS patients. Consequently, an 
unknown but substantial proportion of these patients may be over-
treated, rendering knowledge about late adverse effects after DCIS 
treatment of great importance.
Treatment of DCIS typically consists of surgery, and in the 
case of wide local excision, this is often followed by radiation 
using tangential breast fields. Previous research has shown that 
radiation exposure of the heart, for instance in patients treated for 
Hodgkin lymphoma (6–8) and invasive BC (9, 10), can increase 
the long-term risk of cardiovascular disease (CVD). Exposures 
to lower doses (<2 Gy) have also been shown to increase the risk 
of CVD, although this concerned whole body irradiation with 
potential vascular damage to other organs (eg, kidneys) (11,12). 
Recently, a dose–effect relationship for ischemic heart disease 
(IHD) was shown in BC patients treated with radiotherapy (13). 
Radiation in DCIS treatment will result in exposure of the heart, 
but with relatively low doses (estimated mean heart dose during 
study period is approximately 6 Gy for left-sided disease and 2 Gy 
for right-sided) (14) compared with, for example, exposure from 
treatment for invasive BC that also included nodal fields. Yet, 
until now, only three studies have examined treatment-related 
CVD in DCIS patients (15–17), and the results were inconsistent. 
Because these studies examined cardiovascular mortality rather 
than morbidity (15,16) or included rather few patients (17), it 
remains unclear whether patients treated with radiotherapy for 
DCIS are at increased risk for CVDs. We therefore studied the 
risk of cardiovascular morbidity and mortality in a large popula-
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Methods
Data Collection Procedures
The Dutch population-based DCIS cohort consists of 10 468 female 
patients diagnosed with DCIS as their first neoplasia before the age 
of 75 years between 1989 and 2004. Patient selection was performed 
by the Netherlands Cancer Registry (NCR). The NCR has a cover-
age of at least 96% of invasive malignant neoplasms and selected 
noninvasive cancers, including DCIS, occurring in the Netherlands 
since 1989 (18). The NCR performs an annual linkage with the 
population-based municipal personal records database for date of 
death. For both initial DCIS and subsequent neoplasia, the NCR 
provided date of birth, diagnosis, and death; topography; morphol-
ogy; differentiation; stage; type of surgery; whether chemotherapy 
was administered; and whether radiotherapy was administered.
Linkages with two different population-based registries were 
performed for CVD information (see Supplementary Methods, 
available online, for linkage details). First linkage was with 
the Cardiac Intervention Registry maintained by the Steering 
Committee Heart Interventions Netherlands (BHN). This popula-
tion-based registry collects data on all heart interventions (includ-
ing open heart surgery and percutaneous coronary interventions) 
performed in the Netherlands since 1995 (19).
After linkage with BHN, the cohort was sent to Statistics 
Netherlands, where linkages were performed for cause of death 
and with the second registry with information on CVD, the Dutch 
Hospital Data (DHD). This registry provides data on all hospital 
discharges. Diagnoses are coded by local hospital staff according to 
the International Classification of Diseases, Ninth Revision (20). 
Because the DHD does not contain a unique personal identifier or 
patient names, linkage with the DHD could be performed only for 
patients who were uniquely identifiable using the variables available 
in the registry (ie, birth date, sex, and four-digit postal code; 90.7% 
of the cohort) (see Supplementary Methods and Supplementary 
Figure 1, available online).
Lack of histological confirmation (n = 9) or treatment including 
chemotherapy (n = 15) were reasons for exclusion. The analytical 
cohort was comprised of 10 444 DCIS patients.
A cardiovascular event was defined as cardiovascular-related hospi-
tal admission/surgical intervention/death. The first hospitalization of 
each specific CVD was used in the analyses. Follow-up on second neo-
plasia, vital status, cardiovascular interventions, and hospital admissions 
were complete until at least January 1, 2010. The study was approved 
by the review boards of the NCR, BHN, and Statistics Netherlands.
Treatment
DCIS was treated with surgery (either mastectomy or wide local 
excision), and, in case of wide local excision, this was, especially in 
the later years, frequently followed by tangential breast field irra-
diation to a prescribed dose equivalent of 50 Gy in 25 fractions. 
(Dose equivalent refers to a measure of biological effectiveness of 
an absorbed dose.) The percentage of DCIS patients treated with 
radiotherapy changed considerably during the study period, from 
20% in 1989 to 46% in 2004.
Statistical Analysis
Because of the anatomical position of the heart, the radiation dose 
to the heart is higher after radiotherapy of the left breast than the 
right breast. Based on primary treatment, we therefore defined three 
mutually exclusive treatment categories: surgery only, radiotherapy 
for right-sided DCIS, and radiotherapy for left-sided DCIS.
We compared cardiovascular mortality in the study population 
with that in the Dutch female population, taking into account per-
son-years of observation in the cohort (by age, calendar period, and 
follow-up interval). From the results of the person-years analysis, we 
calculated standardized mortality ratios (SMRs) as ratios of observed 
and expected numbers of cardiovascular deaths, and we calculated 
absolute excess risk (AER) as observed minus expected, divided by 
the number of person-years at risk, multiplied by 10 000. To quan-
tify the effects of different treatments on CVD risk, within-cohort 
comparisons were performed using competing-risk regression mod-
els (21) with death due to other causes than the event of interest 
as a competing risk and including age at DCIS treatment (continu-
ous) and year of DCIS treatment in the model as covariables. The 
assumptions of proportionality were verified by comparing log-log 
survival curves. Competing-risk regression models were fitted with 
the use of Stata/SE 11.0 (StataCorp LP, College Station, TX), and a 
P value less than .05 was considered statistically significant.
To examine whether patients with a history of CVD are at 
increased risk for developing radiation-induced CVD, as well as to 
rule out confounding by indication, we aimed to take into account 
history of CVD. However, because CVD incidence information 
was available from 1995 onwards only, history of CVD before BC 
diagnosis was not available for all patients and the number of years 
with information on history of CVD increased with year of diagno-
sis after 1995; therefore, a subgroup analysis for patients diagnosed 
between 1997 and 2005 was performed.
Because CVD incidence data in the first 5 years after treatment 
were not available for the entire cohort and because most stud-
ies did not find an increased risk in these first years after radio-
therapy (9,22–24) time at risk of all patients started 5 years after 
DCIS diagnosis in the overall analyses (6 years for patients diag-
nosed with DCIS in 1989) and directly after DCIS diagnosis in the 
subgroup analyses. Events before start of time at risk were ignored 
unless stated differently. Time at risk ended at date of diagnosis of 
the event of interest, date of death, date of diagnosis of a second 
(breast) neoplasia if this neoplasia was treated with chemotherapy 
or radiotherapy above the diaphragm, emigration, or date of most 
recent medical information, whichever came first. Moreover, when 
DHD data were used in analysis, only the first period in time dur-
ing which a person was uniquely identifiable was taken into account 
because linkage with the DHD is not possible for admissions dur-
ing nonunique periods in time.
results
Patient Characteristics
Nearly 54% of the patients were diagnosed with left-sided DCIS 
(Table 1). Patient characteristics did not differ between left- and 
right-sided DCIS. Median follow-up time was 10  years (8  years 
when restricting to patients treated with radiotherapy). Almost 
28% of the cohort was irradiated, mostly after wide local excision. 
During follow-up, 1319 patients died and 2124 were diagnosed 
with a second neoplasia. Few patients (1.7%) had a history of CVD 
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Table 1. Characteristics of the population-based cohort of patients with ductal carcinoma in situ of the breast*
Characteristic
All patients Left-sided DCIS Right-sided DCIS
No.† (%) No. (%) No. (%)
No. of patients 10 444 (100.0) 5613 (53.9) 4825 (46.1)
Age at DCIS diagnosis, y
 <49 2090 (20.0) 1122 (20.0) 967 (20.0)
 49–59 4242 (40.6) 2258 (40.2) 1982 (41.1)
 60–69 3073 (29.4) 1687 (30.1) 1385 (28.7)
 70–74 1039 (9.9) 546 (9.7) 491 (10.2)
Attained age at end of follow-up, y
 <50 586 (5.6) 309 (5.5) 277 (5.7)
 50–59 1923 (18.4) 998 (17.8) 924 (19.2)
 60–69 3567 (34.2) 1919 (34.2) 1648 (34.2)
 70–79 3180 (30.4) 1758 (31.3) 1419 (29.4)
 ≥80 1188 (11.4) 629 (11.2) 557 (11.5)
Treatment period DCIS
 1989–1992 1382 (13.2) 757 (13.5) 625 (13.0)
 1993–1996 2373 (22.7) 1268 (22.6) 1102 (22.8)
 1997–2000 3096 (29.6) 1702 (30.3) 1394 (28.9)
 2001–2004 3590 (34.4) 1886 (33.6) 1704 (35.3)
Follow-up time, median, y 10 10 10
 Patients treated with radiotherapy, median, y 8 8 8
Follow-up interval, y
 0 7 (0.1) 3 (0.1) 4 (0.1)
 <5 481 (4.6) 251 (4.5) 230 (4.8)
 5–9 4653 (44.6) 2487 (44.3) 2165 (44.9)
 10–14 3366 (32.2) 1834 (32.7) 1528 (31.7)
 ≥15 1937 (18.5) 1038 (18.5) 898 (18.6)
Primary DCIS treatment
 Surgery only 7466 (71.5) 3985 (71.0) 3476 (72.0)
   Mastectomy 4434 (42.5) 2318 (41.3) 2113 (43.8)
   Lumpectomy 2014 (19.3) 1113 (19.8) 900 (18.7)
   Type of surgery unknown‡ 1018 (9.7) 554 (9.9) 463 (9.6)
 Surgery and radiotherapy 2899 (27.8) 1584 (28.2) 1314 (27.2)
   Mastectomy and radiotherapy 111 (1.1) 63 (1.1) 48 (1.0)
   Lumpectomy and radiotherapy 2543 (24.3) 1393 (24.8) 1149 (23.8)
   Type of surgery unknown‡ and radiotherapy 236 (2.3) 126 (2.2) 110 (2.3)
 Untreated§ 79 (0.8) 44 (0.8) 35 (0.7)
Vital status
 Alive 8916 (85.4) 4775 (85.1) 4135 (85.7)
 Dead 1319 (12.6) 724 (12.9) 595 (12.3)
 Emigrated 209 (2.0) 114 (2.0) 95 (2.0)
Patients ever uniquely identifiable during follow-up|| 9470 (90.7) 5081 (90.5) 4389 (91.0)
Laterality
 Left 5613 (53.7)
 Right 4825 (46.2)
 Unknown 6 (0.1)
Differentiation DCIS
 Well-differentiated 968 (9.3) 537 (9.6) 430 (8.9)
 Moderately differentiated 1715 (16.4) 909 (16.2) 805 (16.7)
 Poorly differentiated 2788 (26.7) 1462 (26.0) 1326 (27.5)
 Unknown¶ 4973 (47.6) 2705 (48.2) 2264 (46.9)
History of cardiovascular disease# 182 (1.7) 97 (1.7) 84 (1.7)
 DCIS diagnosis 1989–1992** NA NA NA
 DCIS diagnosis 1993–1996** 9 (0.1) 4 (0.1) 5 (0.1)
 DCIS diagnosis 1997–2000 58 (0.6) 33 (0.6) 25 (0.5)
 DCIS diagnosis 2001–2004 114 (1.1) 60 (1.1) 54 (1.1)
Second primary neoplasia 2124 (20.3) 1188 (21.2) 936 (19.4)
* DCIS = ductal carcinoma in situ of the breast; NA = not available.
† The numbers of left-sided and right-sided DCIS do not add up to the total because of six patients with missing laterality.
‡ Type of surgery was not registered in every region during the first years of the registry.
§ Excluded from analyses.
|| Linkage with the Hospital Discharge Registry is only possible for patients who were ever unique based on postal code, date of birth, and sex.
¶ Time dependent, with “unknown” coded more often during older years of diagnoses.
# History of cardiovascular disease defined as a hospital admission for cardiovascular disease or cardiovascular before the DCIS diagnosis.
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In total, 950 patients experienced a cardiovascular event, of 
whom 814 were admitted to the hospital, 255 underwent a car-
diovascular intervention, and 282 died due to CVD (Table  2). 
Considering events occurring 5 or more years after DCIS diagno-
sis only, 684  events remained for analyses, of which 574 were hos-
pital admissions, 170 were cardiovascular interventions, and 204 
were cardiovascular deaths.
Comparison With the General Population
Compared with the general population, 5-year survivors of DCIS 
had a similar risk of dying from any cause (SMR = 1.04; 95% con-
fidence interval [CI] = 0.97 to 1.11). However, cardiovascular mor-
tality, including both cardiovascular and cerebrovascular diseases, 
was lower for DCIS patients, with a standardized mortality ratio 
of 0.77 (95% CI = 0.67 to 0.89) (Table 3). Standardized mortality 
ratios did not vary by age at diagnosis, treatment period, follow-up 
interval, or treatment, or for all cardiovascular deaths combined 
or death due to myocardial infarction, other IHD, or other heart 
disease separately (Table 4).
Within-Cohort Comparison
When comparing patients treated with radiotherapy to patients 
treated with surgery only and patients treated with left-sided vs 
right-sided radiotherapy, no statistically significantly increased 
risks were found for the combined group of any cardiovascular 
event (hazard ratio [HR] = 0.94; 95% CI = 0.67 to 1.32), or for 
Table 2. Cardiovascular events in the population-based ductal carcinoma in situ of the breast cohort*
Cardiovascular event ICD-10 Total, No. 5-year survivors,† No.
Any cardiovascular event‡ 950 684
 Cardiovascular death I00-99 282 204
  Myocardial infarction I21-22 76 48
  Other ischemic heart disease I20, 23–25 25 15
  Other heart disease I30-52 78 63
  Pericarditis I30-32 0 0
  Valvular dysfunction I34-38 17 15
  Cardiomyopathy I42 2 2
  Arrhythmia I47-49 10 6
  Congestive heart failure I50 23 18
  Cerebrovascular disease I60-69 68 55
 Hospital admission for cardiovascular disease§ I20-25, 30-52 814 574
  Ischemic heart disease I20-25 411 268
  Acute myocardial infarction I21-22 137 83
  Angina pectoris I20 146 88
  Valvular dysfunction I34-38 52 39
  Arrhythmia I47-49 308 215
  Congestive heart failure I50 154 120
 Surgical intervention for cardiovascular disease|| 255 170
  Percutaneous coronary intervention 158 101
  Coronary artery bypass surgery 56 36
  Valvular dysfunction 53 41
  Arrhythmia 4 3
* ICD-10 = International Classification of Diseases, 10th Revision.
† Time at risk started 5 years after DCIS diagnosis.
‡ Cardiovascular death, hospital admission for cardiovascular disease, or surgical intervention for cardiovascular disease.
§ Data available since 1995 for patients who were unique based on date of birth, sex, and postal code at time of the hospital discharge.
|| Data available since 1995.
Table 3. Standardized mortality ratios in population-based cohort of 5-year survivors of ductal carcinoma in situ of the breast*
Cause ICD-10 Observed SMR (95% CI) AER
All causes† A00-Y89 941 1.04 (0.97 to 1.11) 5.7
Unknown cause 6
Circulatory system I00-99 195 0.77 (0.67 to 0.89) −10.2
 Myocardial infarction I21-22 43 0.83 (0.60 to 1.11) −1.6
 Other ischemic heart disease I20, 23-25 15 0.78 (0.44 to 1.29) −0.7
 Other heart disease I30-33, 39-52 47 0.69 (0.50 to 0.91) −3.8
 Cerebrovascular disease I60-69 52 0.77 (0.58 to 1.01) −2.7
 Other cardiovascular disease I00-15, 26-28, 34-52, 70-99 38 0.83 (0.59 to 1.14) −1.4
* Time at risk started 5 years after ductal carcinoma in situ diagnosis. Patients were censored at diagnosis of a second neoplasia treated with chemotherapy or 
radiotherapy above the diaphragm or date of emigration. AER = absolute excess risk per 10,000 patients per year; CI = confidence interval; ICD-10 = International 
Classification of Diseases, 10th Revision; SMR = standardized mortality ratio.
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cardiovascular death, cardiovascular surgical intervention, hospital 
discharge diagnoses of CVD, myocardial infarction, other heart 
disease, valvular dysfunction, arrhythmia, or congestive heart fail-
ure separately (Table 5). Risks of hospital discharge diagnoses for 
IHD and angina pectoris were increased for patients treated with 
right-sided radiotherapy compared with surgery only (HR = 1.47, 
95% CI = 1.01 to 2.13; HR = 2.53; 95% CI = 1.46 to 4.41, respec-
tively). However, no statistically significant differences were seen 
comparing left-sided vs right-sided radiotherapy (HR = 0.78, 95% 
CI = 0.48 to 1.27 for IHD; HR = 0.57, 95% CI = 0.27 to 1.23 for 
angina pectoris). Although non-statistically significant, risks of car-
diovascular mortality, IHD, congestive heart failure, and cardiovas-
cular surgical interventions tended to be lower for patients treated 
with radiotherapy to the left breast than for patients irradiated to the 
right breast. Conversely, risks of valvular dysfunction and arrhyth-
mia were somewhat higher, although not statistically significantly, 
for left-sided vs right-sided radiotherapy.
In a subgroup analysis of patients diagnosed with DCIS between 
1997 and 2005, with time at risk starting directly after DCIS diag-
nosis and taking into account history of CVD, we did not observe 
a risk difference between treatment groups (adjusted estimate for 
left-sided vs right-sided radiotherapy: HR = 0.94, 95% CI = 0.68 
to 1.29) (Table 6). Additionally, the risk in the first 5  years after 
treatment did not differ from the risk more than 5 years after treat-
ment (HR = 0.63; 95% CI = 0.42 to 0.94). In stratified analyses, 
similar risks were found for patients with and without a history 
of CVD (HR  =  0.88, 95% CI  =  0.37 to 2.06; HR  =  0.94, 95% 
CI = 0.67 to 1.33, respectively). When taking into account history 
of CVD within 2  years before DCIS diagnosis only, thus equal-
ing the number of years with information on history of CVD for 
all patients, a non-statistically significant risk increase of 1.85 was 
seen for patients with a history of CVD (95% CI = 0.50 to 6.82), 
whereas no increased risk was seen for patients without a history of 
CVD (HR = 0.95; 95% CI = 0.68 to 1.33). However, the number of 
patients available for this analysis was small.
Discussion
In this large population-based cohort study, we observed that, com-
pared with the general population, 5-year survivors of DCIS had a 
decreased risk of cardiovascular death, independent of treatment. 
After a median follow-up of 10 years, we did not find an increased 
risk for cardiovascular morbidity or mortality after radiotherapy 
treatment for DCIS. We compared patients treated with radiother-
apy vs those treated with surgery only, as well as patients treated with 
radiotherapy for left-sided vs right-sided DCIS. Overall, history of 
CVD before DCIS diagnosis did not seem to increase the risk of 
radiation-associated CVD. When taking into account cardiovascular 
events that occurred 2 years before DCIS diagnosis only, however, 
a non-statistically significantly increased risk was seen for patients 
with a history of CVD. Because of the low number of patients with a 
history of CVD in this analysis, this may be a chance finding.
Contrary to our expectations, we did not find a risk increase of 
IHD incidence or mortality after radiotherapy for DCIS, possibly 
because of the relatively short follow-up duration. Excess risks for 
valvular dysfunction, arrhythmia, and congestive heart failure were 
not expected because of the expected low mean heart dose.
Although we did not collect information on radiation fields, it is 
plausible to assume that patients treated with radiotherapy were irra-
diated using tangential breast fields only. In the Netherlands, DCIS 
and invasive BC are treated with similar tangential fields (provided 
internal mammary nodes are not included); therefore our results also 
apply to invasive BC patients. The Early BC Trialists’ Collaborative 
Group (15) compared DCIS patients (n = 3729) treated with radio-
therapy to patients treated with surgery only and found a slight but 
non-statistically significant risk increase in cardiovascular mortality. 
Although we had a comparable follow-up duration, we were not able 
to confirm this finding. Our results are, however, in line with the two 
other CVD studies in DCIS patients (16,17). Ernster et al. (16) found 
a similarly decreased standardized mortality ratio for CVD using the 
Surveillance, Epidemiology and End Results database (n  =  7072). 
However, they were not able to make any further distinctions based on 
laterality or treatment. Also in invasive BC patients, lower standardized 
mortality ratios were found (22,24). Possible explanations for lower 
standardized mortality ratios for CVD are differences in CVD risk 
factors between DCIS patients and the general population (eg, higher 
socioeconomic status, later age at menopause, or being more health-
conscious or adopting a healthier lifestyle after DCIS diagnosis).
Park et al. (17) compared cardiovascular morbidity and mortality in 
a small patient group (n = 129) treated with radiotherapy for left-sided 
vs right-sided DCIS and did not find a difference. Studies looking at 
the effect of tangential breast field irradiation for invasive BC showed 
mixed results (25,26). Our results are in contrast with Darby et al.’s (13) 
recently published increase of IHD risk of 7.4% per Gy mean heart 
dose. We have no clear explanation why the results of our study do not 
point to an increased risk after left-sided RT, but possible explanations 
include a much narrower mean heart radiation dose range in our study 
and differences between the two studies with regard to the calendar 
periods in which the patients were treated in combination with changes 
in cardiovascular risk management in these calendar periods.
We used two treatment groups as internal reference groups: 
right-sided radiotherapy and surgery only. It has been discussed 
whether the latter group is an appropriate comparison group. Some 
researchers argue that patients treated with surgery only might dif-
fer from patients treated with radiotherapy on CVD risk factors 
(10). However, because of the excellent Dutch health insurance sys-
tem and the small distances to radiation facilities, only comorbidity 
could have influenced the treatment choice, next to DCIS disease 
characteristics and patient preferences. If comorbidity had an influ-
ence, the effect was probably small because the prevalence of a his-
tory of CVD before DCIS diagnosis was low (1.7%) in our patient 
population aged 75 years or younger at DCIS diagnosis. Moreover, 
patients with a history of CVD did not receive radiotherapy less 
often than patients without a history of CVD, and estimates com-
paring radiotherapy vs surgery only did not materially differ from 
those of left-sided vs right-sided radiotherapy comparisons.
Our study had several strengths and limitations. Unique fea-
tures of our population-based study include taking into account 
both cardiovascular morbidity and mortality, performing linkage 
with two population-based registries with CVD information, and 
examining the effect of a history of CVD.
There is no reason to assume either confounding by indication 
or surveillance bias in our study population. There was no differ-






/jnci/article-abstract/106/8/dju156/906508 by guest on 23 January 2020
JNCI | Article 7 of 9jnci.oxfordjournals.org
Table 5. Competing risk regression analyses for different cardiovascular events in 5-year survivors of ductal carcinoma in situ*
Risk factor ICD-10 No. of events HR (95% CI)
Any cardiovascular event†,‡ 613
 Surgery only 475 1.00 (Referent)
 Right-sided radiotherapy 65 1.08 (0.83 to 1.41)
 Left-sided radiotherapy 73 1.01 (0.79 to 1.30)
 Left- vs right-sided radiotherapy 138 0.94 (0.67 to 1.32)
Cardiovascular death§ I20-25, 30-52 125
 Surgery only 101 1.00 (Referent)
 Right-sided radiotherapy 13 1.29 (0.72 to 2.31)
 Left-sided radiotherapy 11 0.89 (0.48 t0 1.66)
 Left- vs right-sided radiotherapy 24 0.70 (0.31 to 1.56)
Hospital discharge diagnosis of cardiovascular disease‡ I20-25, 30-52 542
 Surgery only 416 1.00 (Referent)
 Right-sided radiotherapy 59 1.12 (0.85 to 1.48)
 Left-sided radiotherapy 67 1.07 (0.82 to 1.38)
 Left- vs right-sided radiotherapy 126 0.95 (0.67 to 1.36)
Hospital discharge diagnosis of ischemic heart disease‡ I20-25 253
 Surgery only 189 1.00 (Referent)
 Right-sided radiotherapy 33 1.47 (1.01 to 2.13)
 Left-sided radiotherapy 31 1.15 (0.78 to 1.68)
 Left- vs right-sided radiotherapy 64 0.78 (0.48 to 1.27)
Hospital discharge diagnosis of acute myocardial infarction‡ I21 75
 Surgery only 62 1.00 (Referent)
 Right-sided radiotherapy 8 1.13 (0.54 to 2.40)
 Left-sided radiotherapy 5 0.59 (0.24 to 1.48)
 Left- vs right-sided radiotherapy 13 0.52 (0.17 to 1.63)
Hospital discharge diagnosis of angina pectoris‡ I20 82
 Surgery only 55 1.00 (Referent)
 Right-sided radiotherapy 16 2.53 (1.46 to 4.41)
 Left-sided radiotherapy 11 1.43 (0.76 to 2.71)
 Left- vs right-sided radiotherapy 27 0.57 (0.27 to 1.23)
Hospital discharge diagnosis of other heart disease† I30-52 340
 Surgery only 266 1.00 (Referent)
 Right-sided radiotherapy 31 0.89 (0.61 to 1.31)
 Left-sided radiotherapy 43 1.05 (0.76 to 1.46)
 Left- vs right-sided radiotherapy 74 1.19 (0.75 to 1.91)
Hospital discharge diagnosis of valvular dysfunction‡ I34-38 37
 Surgery only 29 1.00 (Referent)
 Right-sided radiotherapy 3 0.83 (0.25 to 2.71)
 Left-sided radiotherapy 5 1.18 (0.47 to 2.94)
 Left- vs right-sided radiotherapy 8 1.51 (0.36 to 6.28)
Hospital discharge diagnosis of arrhythmia‡ I47-49 205
 Surgery only 157 1.00 (Referent)
 Right-sided radiotherapy 20 0.91 (0.57 to 1.48)
 Left-sided radiotherapy 28 1.09 (0.73 to 1.64)
 Left- vs right-sided radiotherapy 48 1.20 (0.67 to 2.15)
Hospital discharge diagnosis of congestive heart failure‡ I50 107
 Surgery only 87 1.00 (Referent)
 Right-sided radiotherapy 10 1.04 (0.53 to 2.03)
 Left-sided radiotherapy 10 0.87 (0.45 to 1.67)
 Left- vs right-sided radiotherapy 20 0.83 (0.34 to 2.03)
Cardiovascular surgical intervention§ 164
 Surgery only 125 1.00 (Referent)
 Right-sided radiotherapy 20 1.44 (0.89 to 2.36)
 Left-sided radiotherapy 19 1.12 (0.69 to 1.82)
 Left- vs right-sided radiotherapy 39 0.78 (0.41 to 1.46)
* With death treated as a competing risk. Adjusted for age at ductal carcinoma in situ (DCIS) diagnosis and year of DCIS diagnosis. Patients were censored at 
diagnosis of a second neoplasia treated with chemotherapy or radiotherapy above the diaphragm or date of emigration. Multiple cardiovascular events per person 
possible. CI = confidence interval; HR = hazard ratio; ICD-10 = International Classification of Diseases, 10th Revision.
† Cardiovascular death, hospital admission for cardiovascular disease, or surgical intervention for cardiovascular disease.
‡ Time at risk started at the first moment of becoming uniquely identifiable, with a minimum of 5 years after DCIS diagnosis.
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DCIS, history of CVD incidence did not differ by laterality, and 
DCIS patients irradiated to the breast are not routinely screened 
for cardiac symptoms in routine clinical care.
A limitation of our study is that we missed less-severe cases of 
CVD that did not require hospitalization or cardiac intervention and 
did not lead to death. Furthermore, we were unable to perform linkage 
with the DHD for 9.7% of our cohort because these patients were not 
uniquely identifiable. There is, however, no reason to assume differ-
ence in CVD incidence between identified and nonidentified patients 
because no differences in patient characteristics or frequency of car-
diovascular surgical interventions between the two groups were found.
Cardiovascular surgical interventions always include a hospi-
tal admission of at least 1 day. Therefore, in theory, all interven-
tions provided by BHN should be present in the DHD database. 
Contrary to BHN, which is nearly complete since 2001, the com-
pleteness of the DHD has declined since 2003 from 99.4% to 
87.3% in 2009. This decreased completeness is caused by a decline 
in participation in the DHD registry among hospitals. Yet, because 
hospital admissions for general CVDs are indiscriminately distrib-
uted among hospitals, the effect of the incompleteness for general 
CVDs is thought to be random. Only serious cardiovascular surgi-
cal interventions are limited to certain hospitals in the Netherlands. 
Such interventions are registered by BHN. Therefore, linkage with 
both population-based registries ensured a high coverage of CVD 
with only some random incompleteness of the less severe CVDs.
Because the DHD and the BHN registries were digitalized/
initiated in 1995, CVD incidence before 1995 was unavailable for 
our cohort. Therefore, we included only 5-year survivors in our 
overall analyses. Because earlier research has frequently shown 
that radiotherapy-related CVD risk did not become clinically 
manifest until after 5 to 10  years (9,22–24), no effect of radio-
therapy was expected in the first 5 years after irradiation. In our 
analyses in patients diagnosed in 1997 or later, we did not observe 
risk increases in the first 5 years after treatment.
Unfortunately, we did not have information on CVD risk fac-
tors. However, it is unlikely that any possible risk factor would dif-
fer by laterality.
Especially because radiation effects on CVD have a long induc-
tion period, it is unfortunate that the follow-up in our study was 
relatively short, with a median of 10 years in the total cohort and 
8 years for patients treated with radiotherapy. Although restriction 
of the analyses to patients with a follow-up of 10 years or more did 
not change our results, power was limited in these analyses.
The results of our study are important for the debate with regard 
to screening for BC and the possibility of overtreating the increas-
ing number of patients diagnosed with DCIS. Possible benefits and 
risks of BC screening and radiotherapy after breast-conserving sur-
gery for DCIS should be weighed carefully. Importantly, radiother-
apy after breast-conserving surgery for DCIS approximately halves 
the rate of ipsilateral breast events during the subsequent decade 
with little effect on contralateral or distant events (15). Although 
our results are reassuring, studies with longer follow-up after breast 
irradiation are needed before definitive conclusions regarding CVD 
risk can be drawn.
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